Results 31 to 40 of about 99,753 (275)

Peripheral T-Cell Lymphomas of the T Follicular Helper Type: Clinical, Pathological, and Genetic Attributes

Hemato, 2022
Follicular helper T-cell (TFH) lymphomas comprise a unique group of T-cell lymphomas that represent neoplastic proliferations of follicular helper T-cells and share genetic, immunophenotypic, morphologic, and clinical features.
Karthik A. Ganapathi, Kristin H. Karner, Madhu P. Menon   +2 more
doaj   +1 more source

Outcomes and Prognostic Factors in Angioimmunoblastic T cell Lymphoma: Final Report from the International TCell Project.

Blood, 2021
Angioimmunoblastic T-cell lymphoma (AITL) is a unique subtype of peripheral T-cell lymphoma (PTCL) with distinct clinicopathologic features and poor prognosis. We performed a subset analysis of 282 patients with AITL enrolled between 2006 and 2018 in the
R. Advani, T. Skrypets, M. Civallero, M. Spinner, M. Manni, Won-Seog Kim, A. Shustov, S. Horwitz, F. Hitz, M. Cabrera, I. Dlouhy, J. Vassallo, S. Pileri, G. Inghirami, S. Montoto, U. Vitolo, J. Radford, J. Vose, M. Federico   +18 more
semanticscholar   +1 more source

Angioimmunoblastic T-cell lymphoma and correlated neoplasms with T-cell follicular helper phenotype: from molecular mechanisms to therapeutic advances

Frontiers in Oncology, 2023
Angioimmunoblastic T-cell lymphoma (AITL) is the second most frequent subtype of mature T-cell lymphoma (MTCL) in the Western world. It derives from the monoclonal proliferation of T-follicular helper (TFH) cells and is characterized by an exacerbated ...
L. A. Lage, H. Culler, C. O. Reichert, Sheila Aparecida Coelho da Siqueira, J. Pereira   +4 more
semanticscholar   +1 more source

Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma.

Blood Advances, 2021
Angioimmunoblastic T-cell lymphoma (AITL) is a frequent T-cell lymphoma in the elderly population that has a poor prognosis when treated with cyclophosphamide, doxorubicin, vincristine, and prednisone  (CHOP) therapy.
F. Lemonnier, V. Safar, A. Beldi-Ferchiou, A. Cottereau, E. Bachy, G. Cartron, V. Fataccioli, L. Pelletier, C. Robe, A. Létourneau, E. Missiaglia, S. Fourati, M. Moles-Moreau, A. Delmer, R. Bouabdallah, L. Voillat, S. Becker, C. Bossard, M. Parrens, O. Casasnovas, V. Cacheux, C. Régny, V. Camus, M. Delfau-Larue, M. Meignan, L. de Leval, P. Gaulard, C. Haioun   +27 more
semanticscholar   +1 more source

Angioimmunoblastic T-cell lymphoma [PDF]

Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2011
Review on Angioimmunoblastic T-cell lymphoma, with data on clinics, and the genes involved.
A Cuneo, GL Castoldi
openaire   +2 more sources

Chidamide plus prednisone, etoposide, and thalidomide for untreated angioimmunoblastic T‐cell lymphoma in a Chinese population: A multicenter phase II trial

American journal of hematology/oncology, 2022
Angioimmunoblastic T‐cell lymphoma (AITL) is a common type of peripheral T‐cell lymphoma (PTCL) with a poor prognosis, and an effective first‐line therapy is lacking.
Yawen Wang, Mingzhi Zhang, Wei Song, Q. Cai, Liling Zhang, Xiuhua Sun, L. Zou, Huilai Zhang, Lili Wang, H. Xue   +9 more
semanticscholar   +1 more source

Conjunctival Angioimmunoblastic T-Cell Lymphoma [PDF]

Ocular Oncology and Pathology, 2014
Angioimmunoblastic T-cell lymphoma (AITL) represents an uncommon variant of T-cell lymphomas and most often presents insidiously with systemic symptoms. This report constitutes the first documented case of conjunctival AITL, masquerading as nodular episcleritis, and describes both the clinical and pathological findings. Furthermore, conjunctival T-cell
Darshak S. Patel, Paul Rundle, Sachin M. Salvi, Malee Fernando, Hardeep Singh Mudhar   +4 more
openaire   +3 more sources

A phase I dose-escalation study of neoantigen-activated haploidentical T cell therapy for the treatment of relapsed or refractory peripheral T-cell lymphoma

Frontiers in Oncology, 2022
Peripheral T-cell lymphoma (PTCL) is a type of highly heterogeneous non-Hodgkin lymphoma with a poor prognosis and lack of effective targeted therapies. Adoptive T-cell therapy has been successfully used in the treatment of B-cell malignancies.
Yuan Chen, Hu Zhao, Jing Luo, Youping Liao, Xu Dan, Guoyu Hu, Weiyue Gu   +6 more
doaj   +1 more source

Inhibition of choline metabolism in an angioimmunoblastic T-cell lymphoma preclinical model reveals a new metabolic vulnerability as possible target for treatment. [PDF]

J Exp Clin Cancer Res
Background Angioimmunoblastic T-cell lymphoma (AITL) is a malignancy with very poor survival outcome, in urgent need of more specific therapeutic strategies. The drivers of malignancy in this disease are CD4+ follicular helper T cells (Tfh).
Krug A, Tosolini M, Madji Hounoum B, Fournié JJ, Geiger R, Pecoraro M, Emond P, Gaulard P, Lemonnier F, Ricci JE, Verhoeyen E.   +10 more
europepmc   +2 more sources

Epstein–Barr virus positive diffuse large B‐cell lymphoma transformed into angioimmunoblastic T‐cell lymphoma after treatment

Clinical Case Reports, 2021
Angioimmunoblastic T‐cell lymphoma (AITL) is the subtype of mature T‐cell non‐Hodgkin lymphoma. Compared with diffuse large B‐cell lymphoma (DLBCL), AITL patients are frequently accompanied with Epstein–Barr virus (EBV) infection.
Chaoyu Wang, Yi Gong, Qingming Jiang, Xiping Liang, Rui Chen   +4 more
doaj   +1 more source